NEW YORK (GenomeWeb News) – Gentel Biosciences will collaborate with an international consortium focused on developing biomarkers for pregnancy complications, the company said.

The Screening for Pregnancy Endpoints (SCOPE) Study is establishing a pregnancy biobank that will be used to research tests that can predict major diseases of late-stage pregnancy, which affect 19 percent of worldwide pregnancies, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.